FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2415178657> ?p ?o ?g. }

• W2415178657 endingPage "41241" @default.
• W2415178657 startingPage "41233" @default.
• W2415178657 abstract "// Rudolf A. Werner 1,2 , Seval Beykan 1 , Takahiro Higuchi 1,2 , Katharina Lückerath 1 , Alexander Weich 3 , Michael Scheurlen 3 , Christina Bluemel 1 , Ken Herrmann 1,4 , Andreas K. Buck 1,2 , Michael Lassmann 1 , Constantin Lapa 1,* and Heribert Hänscheid 1,* 1 Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany 2 Comprehensive Heart Failure Center, University Hospital Würzburg, Würzburg, Germany 3 Department of Internal Medicine II, Gastroenterology, University Hospital Würzburg, Würzburg, Germany 4 Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, CA, United States of America * These authors have contributed equally to this work Correspondence to: Heribert Hänscheid, email: // Keywords : renal scintigraphy, MAG3, PRRT, neuroendocrine tumor, 177 Lu Received : April 04, 2016 Accepted : May 23, 2016 Published : June 01, 2016 Abstract Peptide Receptor Radionuclide Therapy (PRRT) for the treatment of neuroendocrine tumors may lead to kidney deterioration. This study aimed to evaluate the suitability of 99m Tc-mercaptoacetyltriglycine ( 99m Tc­-MAG3) clearance for the early detection of PRRT-induced changes on tubular extraction (TE). TE rate (TER) was measured prior to 128 PRRT cycles (7.6±0.4 GBq 177 Lu-octreotate/octreotide each) in 32 patients. TER reduction during PRRT was corrected for age-related decrease and analyzed for the potential to predict loss of glomerular filtration (GF). The GF rate (GFR) as measure for renal function was derived from serum creatinine. The mean TER was 234 ± 53 ml/min/1.73 m² before PRRT (baseline) and 221 ± 45 ml/min/1.73 m² after a median follow-up of 370 days. The age-corrected decrease (mean: -3%, range: -27% to +19%) did not reach significance ( p =0.09) but significantly correlated with the baseline TER (Spearman p =-0.62, p <0.001). Patients with low baseline TER showed an improved TER after PRRT, high decreases were only observed in individuals with high baseline TER. Pre-therapeutic TER data were inferior to plasma creatinine-derived GFR estimates in predicting late nephropathy. TER assessed by 99m Tc-MAG3­clearance prior to and during PRRT is not suitable as early predictor of renal injury and an increased risk for late nephropathy." @default.
• W2415178657 created "2016-06-24" @default.
• W2415178657 creator A5006830341 @default.
• W2415178657 creator A5015450312 @default.
• W2415178657 creator A5021273661 @default.
• W2415178657 creator A5031324764 @default.
• W2415178657 creator A5043348539 @default.
• W2415178657 creator A5045592295 @default.
• W2415178657 creator A5058269910 @default.
• W2415178657 creator A5060665831 @default.
• W2415178657 creator A5083605257 @default.
• W2415178657 creator A5086972055 @default.
• W2415178657 creator A5088874257 @default.
• W2415178657 creator A5091760853 @default.
• W2415178657 date "2016-06-01" @default.
• W2415178657 modified "2023-10-17" @default.
• W2415178657 title "The impact of 177Lu-octreotide therapy on 99mTc-MAG3 clearance is not predictive for late nephropathy" @default.
• W2415178657 cites W1924652994 @default.
• W2415178657 cites W1969170786 @default.
• W2415178657 cites W1970347331 @default.
• W2415178657 cites W1983923913 @default.
• W2415178657 cites W1985061998 @default.
• W2415178657 cites W1995510099 @default.
• W2415178657 cites W1999075032 @default.
• W2415178657 cites W2000340774 @default.
• W2415178657 cites W2008436936 @default.
• W2415178657 cites W2012817319 @default.
• W2415178657 cites W2015579733 @default.
• W2415178657 cites W2016237506 @default.
• W2415178657 cites W2018901137 @default.
• W2415178657 cites W2036789134 @default.
• W2415178657 cites W2063083368 @default.
• W2415178657 cites W2090257199 @default.
• W2415178657 cites W2096981403 @default.
• W2415178657 cites W2125398839 @default.
• W2415178657 cites W2142658652 @default.
• W2415178657 cites W2144007892 @default.
• W2415178657 cites W2156084498 @default.
• W2415178657 cites W2262230090 @default.
• W2415178657 cites W2312352092 @default.
• W2415178657 doi "https://doi.org/10.18632/oncotarget.9775" @default.
• W2415178657 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5173054" @default.
• W2415178657 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27259246" @default.
• W2415178657 hasPublicationYear "2016" @default.
• W2415178657 type Work @default.
• W2415178657 sameAs 2415178657 @default.
• W2415178657 citedByCount "16" @default.
• W2415178657 countsByYear W24151786572016 @default.
• W2415178657 countsByYear W24151786572017 @default.
• W2415178657 countsByYear W24151786572019 @default.
• W2415178657 countsByYear W24151786572020 @default.
• W2415178657 countsByYear W24151786572021 @default.
• W2415178657 countsByYear W24151786572022 @default.
• W2415178657 countsByYear W24151786572023 @default.
• W2415178657 crossrefType "journal-article" @default.
• W2415178657 hasAuthorship W2415178657A5006830341 @default.
• W2415178657 hasAuthorship W2415178657A5015450312 @default.
• W2415178657 hasAuthorship W2415178657A5021273661 @default.
• W2415178657 hasAuthorship W2415178657A5031324764 @default.
• W2415178657 hasAuthorship W2415178657A5043348539 @default.
• W2415178657 hasAuthorship W2415178657A5045592295 @default.
• W2415178657 hasAuthorship W2415178657A5058269910 @default.
• W2415178657 hasAuthorship W2415178657A5060665831 @default.
• W2415178657 hasAuthorship W2415178657A5083605257 @default.
• W2415178657 hasAuthorship W2415178657A5086972055 @default.
• W2415178657 hasAuthorship W2415178657A5088874257 @default.
• W2415178657 hasAuthorship W2415178657A5091760853 @default.
• W2415178657 hasBestOaLocation W24151786571 @default.
• W2415178657 hasConcept C126322002 @default.
• W2415178657 hasConcept C126894567 @default.
• W2415178657 hasConcept C159641895 @default.
• W2415178657 hasConcept C2776297358 @default.
• W2415178657 hasConcept C2779066768 @default.
• W2415178657 hasConcept C2780306776 @default.
• W2415178657 hasConcept C2781025020 @default.
• W2415178657 hasConcept C2989005 @default.
• W2415178657 hasConcept C2993559085 @default.
• W2415178657 hasConcept C71924100 @default.
• W2415178657 hasConceptScore W2415178657C126322002 @default.
• W2415178657 hasConceptScore W2415178657C126894567 @default.
• W2415178657 hasConceptScore W2415178657C159641895 @default.
• W2415178657 hasConceptScore W2415178657C2776297358 @default.
• W2415178657 hasConceptScore W2415178657C2779066768 @default.
• W2415178657 hasConceptScore W2415178657C2780306776 @default.
• W2415178657 hasConceptScore W2415178657C2781025020 @default.
• W2415178657 hasConceptScore W2415178657C2989005 @default.
• W2415178657 hasConceptScore W2415178657C2993559085 @default.
• W2415178657 hasConceptScore W2415178657C71924100 @default.
• W2415178657 hasIssue "27" @default.
• W2415178657 hasLocation W24151786571 @default.
• W2415178657 hasLocation W24151786572 @default.
• W2415178657 hasLocation W24151786573 @default.
• W2415178657 hasLocation W24151786574 @default.
• W2415178657 hasLocation W24151786575 @default.
• W2415178657 hasLocation W24151786576 @default.
• W2415178657 hasOpenAccess W2415178657 @default.
• W2415178657 hasPrimaryLocation W24151786571 @default.
• W2415178657 hasRelatedWork W1544023406 @default.

• next